SCHEMBL26054643

SCHEMBL26054643

CC(C)(C)C(=O)c1ccc(N2CCOCC2)o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 14/20 0.44
MAPT P10636 13/20 0.44
MEN1 O00255 13/20 0.44
ALDH1A1 P00352 10/20 0.44
USP2 O75604 5/20 0.44
KDM4E B2RXH2 5/20 0.44
GAA P10253 5/20 0.44
THRB P10828 2/20 0.44
SMN1; SMN2 Q16637 7/20 0.44
HPGD P15428 6/20 0.44
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
PKM P14618 6/20 0.41
NPSR1 Q6W5P4 4/20 0.40
LMNA P02545 4/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
TDP1 Q9NUW8 3/20 0.40
MAPK1 P28482 2/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26054467 0.86 SMN1; SMN2 (0.47) KMT2AMAPTMEN1ALDH1A1USP2
SCHEMBL26056683 0.75 NPC1 (0.38) KMT2AMAPTMEN1ALDH1A1KDM4E
SCHEMBL23682809 0.73 HDAC6 (0.44) KMT2AMAPTMEN1ALDH1A1KDM4E
SCHEMBL26054728 0.72 MAPT (0.57) KMT2AMAPTMEN1ALDH1A1KDM4E
SCHEMBL26054687 0.69 AKR1C3 (0.48) KMT2AMAPTMEN1ALDH1A1KDM4E
SCHEMBL14212567 0.69 ALDH1A1 (0.47) KMT2AMAPTMEN1ALDH1A1USP2
SCHEMBL23610400 0.69 TDP1 (0.45) KMT2AMAPTMEN1ALDH1A1KDM4E
SCHEMBL1960058 0.68 SMN1; SMN2 (0.73) KMT2AMAPTMEN1ALDH1A1USP2
SCHEMBL21119731 0.68 HRH3 (0.60) KMT2AALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL2625474 0.66 KLK7 (0.50) KMT2AMAPTMEN1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731967-B2 Inhibitors of TRIM33 and methods of use DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731967-B2 Inhibitors of TRIM33 and methods of use TRIM33, TRIM28, TRIM4 KMT2A 1335/4885MAPT 1086/4885MEN1 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.